文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌高剂量图像引导质子治疗后的患者报告性功能生存

Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer.
PubMed 文献 · Radiother Oncol · 2019-02-27

本研究为前瞻性队列研究,纳入1159例接受高剂量图像引导放疗(HD-IGRT)的局限性前列腺癌患者,其中676例基线有勃起功能且未接受激素治疗。6个月、2年和5年勃起功能保留率分别为81%、68%和61%。基于EPIC Q57基线应答和心脏病史可将患者分为3组,5年勃起功能保留率分别为80%、62%和37%。

要点

  • 676例基线有勃起功能且未接受激素治疗者,6个月、2年、5年勃起功能保留率分别为81%、68%、61%。
  • 基于EPIC Q57基线应答和心脏病史分组,5年勃起功能保留率分别为80%、62%、37%。
  • 患者报告的基线性功能和合并症可用于分层和预测勃起功能。

核心结论

  • 患者报告的 pretreatment 性功能和合并症可实现分层并预测勃起功能。
  • EPIC子集问题联合基线合并症可能成为预测性功能生存的快速实用临床工具。

研究设计与样本

  • 前瞻性队列研究,纳入接受HD-IGRT作为前列腺癌主要治疗的局限性前列腺癌患者。
  • 共1159例接受HD-IGRT,其中676例基线有勃起功能且未接受激素治疗纳入分析。
  • 使用患者报告量表在基线、治疗后6个月、2年和5年评估勃起功能。
  • 将长期勃起功能保留率与已验证模型比较,并基于基线因素构建内部验证的列线图。

主要发现

  • 676例基线有勃起功能且未接受激素治疗者,6个月、2年和5年勃起功能保留率分别为81%、68%和61%。
  • 基于EPIC Q57基线应答(勃起能力)和既存心脏病史进行递归分割,将患者分为3组。
  • 5年时,Q57报告「很好」且为最有利组者勃起功能保留率为80%(n=137;p=0.83)。
  • 5年时,Q57报告「好」且无基线心脏病史的中间组勃起功能保留率为62%(n=145;p=0.86)。
  • 5年时,剩余 poor risk 组勃起功能保留率为37%(n=117;p=0.19)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To help guide individualized treatment, we sought to identify baseline predictive factors that impact long-term erectile function following high-dose image-guided radiotherapy (HD-IGRT). METHODS: Potent men with localized prostate cancer treated with radiotherapy alone were enrolled in an institutional review board-approved prospective cohort study. Men received HD-IGRT as primary treatment of prostate cancer. Patient-reported inventories were used to assess erectile function at baseline, 6 months, 2 years, and 5 years after treatment. Long-term potency rates were compared to validated models, and baseline factors were used to create a novel, internally validated nomogram for predicting long-term function. RESULTS: 1,159 men were treated with HD-IGRT. Among 676 men who were potent at baseline and did not receive hormone therapy, the potency rates at 6 months, 2 years, and 5 years were 81%, 68%, and 61%. Recursive partitioning categorized patients into 3 groups based on two factors: baseline response to EPIC Q57 (ability to have an erection) and pre-existing heart disease. At 5 years, the most favorable group reported "very good" on Q57 and had an 80% potency rate (n = 137; p = 0.83); the intermediate group reported "good" on Q57 and had no baseline cardiac disease with a 62% potency rate (n = 145; p = 0.86); and the remaining poor risk group had a 37% potency rate (n = 117; p = 0.19). CONCLUSIONS: Patient-reported pretreatment sexual function and comorbidities enables stratification and prediction of erectile function. EPIC subset questions with baseline comorbidities may potentially serve as a quick and practical clinical tool for predicting sexual survivorship.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Holtzman AL, Bryant CM, Mendenhall NP, et al. Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. Radiother Oncol. 2019. PMID: 31005217. doi:10.1016/j.radonc.2019.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。